CTI BioPharma Corp. (NASDAQ:CTIC) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.63, Bloomberg Earnings reports. The business had revenue of $22.23 million during the quarter. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 1,516.23%.

Shares of CTI BioPharma Corp. (CTIC) traded up 6.41% during midday trading on Friday, hitting $3.65. 63,055 shares of the stock were exchanged. CTI BioPharma Corp. has a one year low of $2.70 and a one year high of $6.48. The stock’s 50-day moving average price is $3.40 and its 200 day moving average price is $4.07. The stock’s market cap is $102.36 million.

Hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in CTI BioPharma Corp. during the first quarter valued at about $181,000. WASHINGTON TRUST Co bought a new stake in CTI BioPharma Corp. during the second quarter valued at about $104,000. Nine Chapters Capital Management LLC increased its stake in CTI BioPharma Corp. by 152.9% in the first quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 26,300 shares during the last quarter. Finally, Segantii Capital Management Ltd bought a new stake in CTI BioPharma Corp. during the first quarter valued at about $102,000. Hedge funds and other institutional investors own 23.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “CTI BioPharma Corp. (CTIC) Releases Earnings Results, Beats Expectations By $0.63 EPS” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/05/cti-biopharma-corp-ctic-releases-earnings-results-beats-expectations-by-0-63-eps.html.

About CTI BioPharma Corp.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.